Difference between revisions of "Team:Manchester/Human Practices"
Huiwenchong (Talk | contribs) |
|||
| Line 293: | Line 293: | ||
<div class="britscweekinfo"> | <div class="britscweekinfo"> | ||
| − | This was the team’s first outreach event! | + | This was the team’s first outreach event! During the British Science Week, we introduced the concept of using synthetic biology in chemical production to pupils and asked for their opinions on the matter. The general feedback led us to believe that our AlcoPatch has the potential of being accepted by the public despite having to genetically modify bacteria. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 306: | Line 306: | ||
<div class="microbioinfo"> | <div class="microbioinfo"> | ||
| − | At the Microbiology Society’s | + | At the Microbiology Society’s annual general conference, we presented the preliminary research we had done into our project. We received feedback from the scientific community on how we can improve the <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach">concept design</a> of our product, which led to the development of our <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach">pilot study</a>. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 319: | Line 319: | ||
<div class="aacademyinfo"> | <div class="aacademyinfo"> | ||
| − | We had a Skype interview with the Alcohol Academy Director, James Morris. He thought that our AlcoPatch would be useful for health professionals, specifically in furthering | + | We had a Skype interview with the Alcohol Academy Director, James Morris. He thought that our AlcoPatch would be useful for <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#nhs">health professionals</a>health professionals, specifically in furthering alcohol brief interventions. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | ||
| Line 332: | Line 332: | ||
<div class="fredsenseinfo"> | <div class="fredsenseinfo"> | ||
| − | We spoke to Mr.David Lloyd, the CEO of a Canada-based biosensor company, FREDsense. | + | We spoke to Mr.David Lloyd, the CEO of a Canada-based biosensor company, FREDsense. While he thought that our AlcoPatch might be useful for reducing <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#gmp">, he raised concerns about <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#gmp">public acceptance</a> of our genetically modified organism (GMO)-based product. The <a href="https://2016.igem.org/Team:Manchester/Description/mechanism1">cell-free mechanism</a>, however, may be more acceptable for the public as it does not involve living GMO. |
| − | While he thought that our AlcoPatch might be useful for reducing | + | |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
| Line 346: | Line 345: | ||
<div class="esofinfo"> | <div class="esofinfo"> | ||
| − | We presented our poster at the | + | We presented our poster at the EuroScience Open Forum where we gained interest from global researchers and deliberated the experience of working in a multi-disciplinary team. From our discussions, we realised that we had difficulties communicating between the disciplines of our members. So in order for us to better understand one another, we took part in a crash-course in <a href="https://2016.igem.org/Team:Manchester/Model">ensemble modelling</a>. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 359: | Line 358: | ||
<div class="meninfo"> | <div class="meninfo"> | ||
| − | Having spoken on the phone to Manchester Evening News, they were very interested in the implications of our AlcoPatch. They decided to publish articles about our project in their paper - twice! | + | Having spoken on the phone to the Manchester Evening News, they were very interested in the implications of our AlcoPatch. They decided to publish articles about our project in their paper - twice! |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 370: | Line 369: | ||
</div> | </div> | ||
<div class="adsinfo1"> | <div class="adsinfo1"> | ||
| − | We | + | We had a discussion with the representatives of this charity to find out if our AlcoPatch would benefit their members. They suggested that our product would be more effective at raising awareness of alcohol consumption than preventing it. They proposed that the <a href="https://2016.igem.org/Team:Manchester/Description/mechanism1">Cell-free Mechanism</a> would be more practical as it may have longer shelf life, <a href="https://2016.igem.org/Team:Manchester/Description/mechanism1">cheaper production costs</a> and only use substances extracted from GMOs. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | ||
| Line 385: | Line 384: | ||
<div class="ibcarbinfo"> | <div class="ibcarbinfo"> | ||
| − | In order to get funding, we pitched our project to the | + | In order to get funding, we pitched our project to Dr. Doherty, the Manager of IBCarb, a networking agency for glyco-scientists. After further talks with IBCarb, we managed to secure the funding for our project - one step closer to the Giant Jamboree! |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
| Line 396: | Line 395: | ||
<div class="experimentinfo"> | <div class="experimentinfo"> | ||
| − | We set up a crowdfunding page on experiment.com | + | We set up a crowdfunding page on <a href="https://experiment.com/projects/alcopatch-a-new-way-of-detecting-alcohol-intoxication">experiment.com</a>, here we reached out to our friends and family asking them to contribute towards our £3000 goal. We also created a <a href="https://www.youtube.com/watch?v=bOEyz6NDHfY">video</a> which complemented the information we uploaded regarding our project. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 407: | Line 406: | ||
<div class="heartfminfo"> | <div class="heartfminfo"> | ||
| − | After publicising the AlcoPatch through Manchester Evening News, Heart FM heard about our project and invited us to speak on their national radio show! | + | After publicising the AlcoPatch through <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach#men">Manchester Evening News</a>, Heart FM heard about our project and invited us to speak on their national radio show! |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Outreach"> More information </a></div> | ||
| Line 420: | Line 419: | ||
<div class="aanonymousinfo"> | <div class="aanonymousinfo"> | ||
| − | We attended an Alcoholics Anonymous meeting where we facilitated a discussion about excessive drinking. After that discussion we gained insight into the motivations behind excessive drinking which influenced our approach towards advertising the AlcoPatch. | + | We attended an Alcoholics Anonymous meeting where we facilitated a discussion about excessive drinking. After that discussion, we gained insight into the motivations behind excessive drinking, which later influenced our approach towards advertising the AlcoPatch. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Charities"> More information </a></div> | ||
| Line 432: | Line 431: | ||
<div class="npronetinfo"> | <div class="npronetinfo"> | ||
| − | We spoke to Ms | + | We spoke to Ms Shephard, the Network Manager of NPRONET, which is a funded network in biotechnology and bioenergy. We reviewed our project and she highlighted the importance of starting the <a href="https://2016.igem.org/Team:Manchester/Description">wet lab work</a> early, in order to complete our project on time. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
| Line 444: | Line 443: | ||
<div class="mancenterpriseinfo"> | <div class="mancenterpriseinfo"> | ||
| − | We spoke to Lynn Shephard (Director) and Dr. Henery (Enterprise Academic Lecturer) of Manchester Enterprise Centre. They educated us in the potential business aspect of our project. They also gave us a few pointers on the entrepreneurship that is needed to produce our AlcoPatch in a real-world context. This led our team to model the cost | + | We spoke to Lynn Shephard (Director) and Dr. Henery (Enterprise Academic Lecturer) of Manchester Enterprise Centre. They educated us in the potential business aspect of our project. They also gave us a few pointers on the entrepreneurship that is needed to produce our AlcoPatch in a real-world context. This led our team to model the <a href="https://2016.igem.org/Team:Manchester/Model">cost effectiveness</a> of our proposed prototype. |
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
</div> | </div> | ||
| Line 455: | Line 454: | ||
<div class="biopronetinfo"> | <div class="biopronetinfo"> | ||
| − | We deliberated our project with Dr. Flannelly (Network Manager) and Prof. Dickinson (Co-Director) from BioProNet, a network in the field of bioprocessing and biologics . They found our project interesting and how the AlcoPatch | + | We deliberated our project with Dr. Flannelly (Network Manager) and Prof. Dickinson (Co-Director) from BioProNet, a network in the field of bioprocessing and biologics . They found our project interesting and agreed with how the AlcoPatch would be useful to students like us. However, they raised concerns with the usage of mildly <a href="https://2016.igem.org/Team:Manchester/Safety">carcinogeneic</a> ABTS dye in our <a href="https://2016.igem.org/Team:Manchester/Description/mechanism1">Cell-free Mechanism</a>. It was suggested that we find suitable alternatives to reduce risks to our potential consumers. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
| Line 467: | Line 466: | ||
<div class="gmpinfo"> | <div class="gmpinfo"> | ||
| − | We spoke to a local Police Community Support Officer (P.C.S.O.) in the area. We asked them for their opinion on how our patch might be of use to the Greater Manchester police force. They gave us some insightful knowledge into the use of breathalysers as well as | + | We spoke to a local Police Community Support Officer (P.C.S.O.) in the area. We asked them for their opinion on how our patch might be of use to the Greater Manchester police force. They gave us some insightful knowledge into the use of breathalysers as well as its limitations with comparison to the potentials of our AlcoPatch. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
| Line 492: | Line 491: | ||
<div class="nhsinfo"> | <div class="nhsinfo"> | ||
| − | A representative from our team spoke to Kelly O’Brien, the Head of Department for Drug Support for Children. She gave us insightful knowledge and feedback on our project relevance to patients with an array of alcohol related issues. She explained that our AlcoPatch would not be beneficial to patients with alcoholism. However, if a prototype were to be made, disseminating the AlcoPatch to the public would enable us to gauge it's effectiveness in educating the public on their intoxication levels. | + | A representative from our team spoke to Kelly O’Brien, the Head of Department for Drug Support for Children. She gave us insightful knowledge and feedback on our project relevance to patients with an array of alcohol-related issues. She explained that our AlcoPatch would not be beneficial to patients with alcoholism issue. However, if a prototype were to be made, disseminating the AlcoPatch to the public would enable us to gauge it's effectiveness in educating the public on their intoxication levels. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
| Line 505: | Line 504: | ||
<div class="wardinfo"> | <div class="wardinfo"> | ||
| − | We | + | We interviewed Andrea Vero, an IP lawyer from Ward Hadaway law firm, to discuss how to protect our intellectual property rights for our AlcoPatch. We also discussed the potential for patenting our AlcoPatch in the future. Ward Hadaway put us in contact with a <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#venner">patent attorney</a> from Venner Shipley to further discuss the matter. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
| Line 518: | Line 517: | ||
<div class="vennerinfo"> | <div class="vennerinfo"> | ||
| − | + | After our meeting with the <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#ward">IP lawyer</a>, we were directed to speak to Matthew Handley, a patent attorney of Venner Shipley. We discussed if our product was suitable for patenting. We deliberated whether it would be realistic to patent our project based on the information we have already disclosed to the public domain. | |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
| Line 531: | Line 530: | ||
<div class="scraminfo"> | <div class="scraminfo"> | ||
| − | We spoke to | + | We spoke to Mark Wojcik, the Chief Technology Officer and Vice President of Engineering of SCRAM Systems, a US-based ethanol biosensor company. He informed us about how their devices function, and how American policies have shaped the needs of law enforcement with regards to alcohol consumption. He educated us on the factors behind the demand for a product like our AlcoPatch and the marketability of our product in the US. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
| Line 544: | Line 543: | ||
<div class="brightsideinfo"> | <div class="brightsideinfo"> | ||
| − | We met with Carley, one of the owners of the family run business Brightside Brewery. She offered her views on how students perceive the AlcoPatch and highlighted the possible applications of our patch in the National Health Service | + | We met with Carley, one of the owners of the family run business Brightside Brewery. She offered her views on how students may perceive the AlcoPatch and highlighted the possible applications of our patch in the <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies#nhs">National Health Service</a>. It was brought to attention that breweries in the UK would have no use for our AlcoPatch. However, she suggested that bars and pubs may be interested in our product. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | <div style="text-align: right;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries"> More information </a></div> | ||
| Line 557: | Line 556: | ||
<div class="fasdinfo"> | <div class="fasdinfo"> | ||
| − | We | + | We had a phone interview with Dr. Mukherjee, the Director of the National Clinic for Fetal Alcohol Spectrum Disorders (FASD). We discussed the relevance of the AlcoPatch with reference to his area of work, Foetal Alcohol Syndrome. It was concluded that his patients will not benefit from a product as such. |
<br /><br /> | <br /><br /> | ||
<div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | <div style="text-align: left;"><a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies"> More information </a></div> | ||
Revision as of 00:28, 16 October 2016
H
U
M
A
N
P
R
A
C
T
I
C
E
S
Hi everyone!! This is the page for our Human Practices that we have done throughout the summer. Aligned with the requirement for iGEM competition, We were always approaching different society and company to get them in recognising our project and aiming to get suggestion or critism on our project. This allowed us to have a clearer picture in the point of view of the public. We categorised each of the activities that we have to 4 different groups. - Charities, Industries, Outreach and Interview. Click on one of the 4 wheels below to find out more!
16
March
23
25
July
26
27
27
28
28
28
28
04
August
04
10
11
13
17
19
02
September
09
20
23
03
October
Timeline
This was the team’s first outreach event! During the British Science Week, we introduced the concept of using synthetic biology in chemical production to pupils and asked for their opinions on the matter. The general feedback led us to believe that our AlcoPatch has the potential of being accepted by the public despite having to genetically modify bacteria.
At the Microbiology Society’s annual general conference, we presented the preliminary research we had done into our project. We received feedback from the scientific community on how we can improve the concept design of our product, which led to the development of our pilot study.
We spoke to Mr.David Lloyd, the CEO of a Canada-based biosensor company, FREDsense. While he thought that our AlcoPatch might be useful for reducing , he raised concerns about public acceptance of our genetically modified organism (GMO)-based product. The cell-free mechanism, however, may be more acceptable for the public as it does not involve living GMO.
We presented our poster at the EuroScience Open Forum where we gained interest from global researchers and deliberated the experience of working in a multi-disciplinary team. From our discussions, we realised that we had difficulties communicating between the disciplines of our members. So in order for us to better understand one another, we took part in a crash-course in ensemble modelling.
Having spoken on the phone to the Manchester Evening News, they were very interested in the implications of our AlcoPatch. They decided to publish articles about our project in their paper - twice!
We had a discussion with the representatives of this charity to find out if our AlcoPatch would benefit their members. They suggested that our product would be more effective at raising awareness of alcohol consumption than preventing it. They proposed that the Cell-free Mechanism would be more practical as it may have longer shelf life, cheaper production costs and only use substances extracted from GMOs.
In order to get funding, we pitched our project to Dr. Doherty, the Manager of IBCarb, a networking agency for glyco-scientists. After further talks with IBCarb, we managed to secure the funding for our project - one step closer to the Giant Jamboree!
We set up a crowdfunding page on experiment.com, here we reached out to our friends and family asking them to contribute towards our £3000 goal. We also created a video which complemented the information we uploaded regarding our project.
After publicising the AlcoPatch through Manchester Evening News, Heart FM heard about our project and invited us to speak on their national radio show!
We attended an Alcoholics Anonymous meeting where we facilitated a discussion about excessive drinking. After that discussion, we gained insight into the motivations behind excessive drinking, which later influenced our approach towards advertising the AlcoPatch.
We spoke to Ms Shephard, the Network Manager of NPRONET, which is a funded network in biotechnology and bioenergy. We reviewed our project and she highlighted the importance of starting the wet lab work early, in order to complete our project on time.
We spoke to Lynn Shephard (Director) and Dr. Henery (Enterprise Academic Lecturer) of Manchester Enterprise Centre. They educated us in the potential business aspect of our project. They also gave us a few pointers on the entrepreneurship that is needed to produce our AlcoPatch in a real-world context. This led our team to model the cost effectiveness of our proposed prototype.
We deliberated our project with Dr. Flannelly (Network Manager) and Prof. Dickinson (Co-Director) from BioProNet, a network in the field of bioprocessing and biologics . They found our project interesting and agreed with how the AlcoPatch would be useful to students like us. However, they raised concerns with the usage of mildly carcinogeneic ABTS dye in our Cell-free Mechanism. It was suggested that we find suitable alternatives to reduce risks to our potential consumers.
We spoke to a local Police Community Support Officer (P.C.S.O.) in the area. We asked them for their opinion on how our patch might be of use to the Greater Manchester police force. They gave us some insightful knowledge into the use of breathalysers as well as its limitations with comparison to the potentials of our AlcoPatch.
UKMeetup
This was the team’s chance to meet other like-minded students and share our project experiences we have had during the summer. We gained valuable feedback from other iGEM teams as well as discussing our project with researchers. We also discussed about the societal impacts of scientific research regarding our project.
A representative from our team spoke to Kelly O’Brien, the Head of Department for Drug Support for Children. She gave us insightful knowledge and feedback on our project relevance to patients with an array of alcohol-related issues. She explained that our AlcoPatch would not be beneficial to patients with alcoholism issue. However, if a prototype were to be made, disseminating the AlcoPatch to the public would enable us to gauge it's effectiveness in educating the public on their intoxication levels.
We interviewed Andrea Vero, an IP lawyer from Ward Hadaway law firm, to discuss how to protect our intellectual property rights for our AlcoPatch. We also discussed the potential for patenting our AlcoPatch in the future. Ward Hadaway put us in contact with a patent attorney from Venner Shipley to further discuss the matter.
After our meeting with the IP lawyer, we were directed to speak to Matthew Handley, a patent attorney of Venner Shipley. We discussed if our product was suitable for patenting. We deliberated whether it would be realistic to patent our project based on the information we have already disclosed to the public domain.
We spoke to Mark Wojcik, the Chief Technology Officer and Vice President of Engineering of SCRAM Systems, a US-based ethanol biosensor company. He informed us about how their devices function, and how American policies have shaped the needs of law enforcement with regards to alcohol consumption. He educated us on the factors behind the demand for a product like our AlcoPatch and the marketability of our product in the US.
We met with Carley, one of the owners of the family run business Brightside Brewery. She offered her views on how students may perceive the AlcoPatch and highlighted the possible applications of our patch in the National Health Service. It was brought to attention that breweries in the UK would have no use for our AlcoPatch. However, she suggested that bars and pubs may be interested in our product.
We had a phone interview with Dr. Mukherjee, the Director of the National Clinic for Fetal Alcohol Spectrum Disorders (FASD). We discussed the relevance of the AlcoPatch with reference to his area of work, Foetal Alcohol Syndrome. It was concluded that his patients will not benefit from a product as such.
